Free Trial

Allogene Therapeutics (ALLO) Financials

Allogene Therapeutics logo
$1.08 +0.02 (+1.89%)
Closing price 04:00 PM Eastern
Extended Trading
$1.08 +0.00 (+0.46%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Allogene Therapeutics

Annual Income Statements for Allogene Therapeutics

This table shows Allogene Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
-258 -327 -340
Consolidated Net Income / (Loss)
-258 -327 -340
Net Income / (Loss) Continuing Operations
-258 -327 -340
Total Pre-Tax Income
-257 -327 -340
Total Operating Income
-273 -328 -336
Total Gross Profit
0.02 0.10 0.16
Total Revenue
0.02 0.10 0.16
Operating Revenue
0.02 0.10 0.16
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
273 328 336
Selling, General & Admin Expense
65 72 79
Research & Development Expense
192 243 256
Impairment Charge
16 13 0.00
Total Other Income / (Expense), net
16 0.47 -4.88
Interest Expense
0.18 0.00 -
Interest & Investment Income
20 18 4.57
Other Income / (Expense), net
-3.92 -18 -9.44
Income Tax Expense
0.44 0.00 -
Basic Earnings per Share
($1.32) ($2.09) ($2.38)
Weighted Average Basic Shares Outstanding
194.81M 156.93M 143.15M
Diluted Earnings per Share
($1.32) ($2.09) ($2.38)
Weighted Average Diluted Shares Outstanding
194.81M 156.93M 143.15M
Weighted Average Basic & Diluted Shares Outstanding
217.26M 169.09M 144.50M
Cash Dividends to Common per Share
$0.00 $0.00 $0.00

Quarterly Income Statements for Allogene Therapeutics

This table shows Allogene Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-60 -66 -66 -65 -86 -62 -79 -100 -103 -83
Consolidated Net Income / (Loss)
-60 -66 -66 -65 -86 -62 -79 -100 -103 -83
Net Income / (Loss) Continuing Operations
-60 -66 -66 -65 -86 -62 -79 -100 -103 -83
Total Pre-Tax Income
-59 -66 -66 -65 -86 -62 -79 -100 -103 -83
Total Operating Income
-60 -72 -71 -70 -85 -63 -81 -99 -96 -82
Total Operating Expenses
60 72 71 70 85 63 81 99 96 83
Selling, General & Admin Expense
16 16 16 17 17 17 19 19 21 19
Research & Development Expense
45 45 50 52 55 46 62 80 75 64
Total Other Income / (Expense), net
0.99 5.48 5.07 4.50 -0.67 0.71 1.31 -0.88 -6.17 -0.66
Other Income / (Expense), net
-7.39 -1.12 0.09 4.50 -8.99 -5.50 -2.47 -0.88 -9.42 -1.66
Basic Earnings per Share
($0.27) ($0.32) ($0.35) ($0.38) ($0.49) ($0.37) ($0.54) ($0.69) ($0.72) ($0.58)
Weighted Average Basic Shares Outstanding
194.81M 209.19M 190.03M 169.13M 156.93M 167.65M 146.80M 144.56M 143.15M 143.66M
Diluted Earnings per Share
($0.27) ($0.32) ($0.35) ($0.38) ($0.49) ($0.37) ($0.54) ($0.69) ($0.72) ($0.58)
Weighted Average Diluted Shares Outstanding
194.81M 209.19M 190.03M 169.13M 156.93M 167.65M 146.80M 144.56M 143.15M 143.66M
Weighted Average Basic & Diluted Shares Outstanding
217.26M 209.67M 209.11M 170.85M 169.09M 168.28M 167.63M 145.84M 144.50M 144.21M

Annual Cash Flow Statements for Allogene Therapeutics

This table details how cash moves in and out of Allogene Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
-7.94 21 -111
Net Cash From Operating Activities
-200 -238 -221
Net Cash From Continuing Operating Activities
-200 -238 -221
Net Income / (Loss) Continuing Operations
-258 -327 -340
Consolidated Net Income / (Loss)
-258 -327 -340
Depreciation Expense
14 14 14
Non-Cash Adjustments To Reconcile Net Income
62 91 102
Changes in Operating Assets and Liabilities, net
-18 -15 3.90
Net Cash From Investing Activities
76 163 106
Net Cash From Continuing Investing Activities
76 163 106
Purchase of Property, Plant & Equipment
-0.69 -1.52 -5.19
Purchase of Investments
-361 -439 -248
Sale and/or Maturity of Investments
438 603 359
Net Cash From Financing Activities
117 96 2.95
Net Cash From Continuing Financing Activities
117 96 2.95
Issuance of Common Equity
114 96 2.95
Other Financing Activities, net
2.28 0.00 -

Quarterly Cash Flow Statements for Allogene Therapeutics

This table details how cash moves in and out of Allogene Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
24 -119 120 -32 14 -86 45 48 -12 -22
Net Cash From Operating Activities
-37 -44 -64 -56 -54 -56 -62 -67 -62 -48
Net Cash From Continuing Operating Activities
-37 -44 -64 -56 -54 -56 -62 -67 -62 -48
Net Income / (Loss) Continuing Operations
-60 -66 -66 -65 -86 -62 -79 -100 -103 -83
Consolidated Net Income / (Loss)
-60 -66 -66 -65 -86 -62 -79 -100 -103 -83
Depreciation Expense
3.23 3.21 3.64 3.56 3.48 3.57 3.64 3.51 3.07 3.86
Non-Cash Adjustments To Reconcile Net Income
13 23 16 9.99 28 22 18 22 26 24
Changes in Operating Assets and Liabilities, net
7.05 -4.35 -17 -4.44 0.93 -19 -4.36 7.42 11 7.79
Net Cash From Investing Activities
55 -76 75 22 67 -34 17 113 50 25
Net Cash From Continuing Investing Activities
55 -76 75 22 67 -34 17 113 50 25
Purchase of Property, Plant & Equipment
-0.26 -0.43 - -0.01 -0.18 -0.01 -0.29 -1.04 -1.69 -0.22
Purchase of Investments
-47 -191 -43 -81 -69 -199 -135 -35 -48 -49
Sale and/or Maturity of Investments
102 115 117 103 136 165 153 149 99 75
Net Cash From Financing Activities
5.74 0.68 109 1.65 0.16 4.29 90 1.73 0.05 1.07
Net Cash From Continuing Financing Activities
5.74 0.68 109 1.65 0.16 4.29 90 1.73 0.05 1.07
Issuance of Common Equity
5.74 0.68 106 1.65 0.16 4.29 90 1.73 0.05 1.07

Annual Balance Sheets for Allogene Therapeutics

This table presents Allogene Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
549 643 822
Total Current Assets
303 459 529
Cash & Equivalents
75 83 62
Short-Term Investments
217 366 455
Prepaid Expenses
11 10 12
Plant, Property, & Equipment, net
86 99 113
Total Noncurrent Assets
159 84 180
Long-Term Investments
81 3.65 76
Other Noncurrent Operating Assets
79 81 103
Total Liabilities & Shareholders' Equity
549 643 822
Total Liabilities
127 131 155
Total Current Liabilities
36 37 54
Accounts Payable
5.39 5.90 14
Accrued Expenses
30 31 40
Total Noncurrent Liabilities
91 94 101
Other Noncurrent Operating Liabilities
91 94 101
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
422 512 667
Total Preferred & Common Equity
422 512 667
Preferred Stock
0.00 0.00 0.00
Total Common Equity
422 512 667
Common Stock
2,242 2,075 1,912
Retained Earnings
-1,820 -1,562 -1,235
Accumulated Other Comprehensive Income / (Loss)
-0.09 -0.96 -9.93

Quarterly Balance Sheets for Allogene Therapeutics

This table presents Allogene Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
589 647 586 712 771 747 888
Total Current Assets
304 457 395 473 502 481 569
Cash & Equivalents
51 171 51 69 155 110 74
Short-Term Investments
240 274 334 396 337 361 478
Prepaid Expenses
13 12 11 7.95 10 10 17
Plant, Property, & Equipment, net
89 92 96 103 106 110 114
Total Noncurrent Assets
196 98 95 136 162 156 204
Long-Term Investments
112 1.13 15 38 62 54 99
Other Noncurrent Operating Assets
84 97 80 99 100 102 105
Total Liabilities & Shareholders' Equity
589 647 586 712 771 747 888
Total Liabilities
125 132 125 129 148 155 148
Total Current Liabilities
33 37 31 38 55 60 49
Accounts Payable
5.51 13 5.78 6.21 10 15 11
Accrued Expenses
27 24 25 31 44 45 37
Total Noncurrent Liabilities
93 95 94 92 93 95 99
Other Noncurrent Operating Liabilities
93 95 94 92 93 95 99
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
464 515 461 583 623 592 740
Total Preferred & Common Equity
464 515 461 583 623 592 740
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
464 515 461 583 623 592 740
Common Stock
2,223 2,209 2,090 2,060 2,039 1,933 1,894
Retained Earnings
-1,760 -1,694 -1,627 -1,474 -1,413 -1,335 -1,141
Accumulated Other Comprehensive Income / (Loss)
0.16 -0.78 -0.93 -2.41 -3.85 -5.93 -13

Annual Metrics And Ratios for Allogene Therapeutics

This table displays calculated financial ratios and metrics derived from Allogene Therapeutics' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
-76.84% -39.10% -99.86%
EBITDA Growth
20.49% -0.21% -90.80%
EBIT Growth
19.81% -0.17% -87.73%
NOPAT Growth
16.64% 2.32% -86.21%
Net Income Growth
21.29% 3.86% -86.99%
EPS Growth
36.84% 12.18% -77.61%
Operating Cash Flow Growth
15.75% -7.81% -19.32%
Free Cash Flow Firm Growth
16.57% 2.80% -32.49%
Invested Capital Growth
-18.13% -18.06% -14.53%
Revenue Q/Q Growth
-48.84% -43.79% -99.79%
EBITDA Q/Q Growth
8.98% 3.55% -49.03%
EBIT Q/Q Growth
8.65% 3.30% -45.34%
NOPAT Q/Q Growth
8.27% 3.35% -41.36%
Net Income Q/Q Growth
9.12% 4.90% -43.21%
EPS Q/Q Growth
14.29% 9.91% -44.24%
Operating Cash Flow Q/Q Growth
7.83% 3.41% -8.17%
Free Cash Flow Firm Q/Q Growth
4.45% 5.52% -35.30%
Invested Capital Q/Q Growth
-18.77% -25.19% -17.48%
Profitability Metrics
- - -
Gross Margin
100.00% 100.00% 100.00%
EBITDA Margin
-1,197,636.36% -348,813.68% -211,977.56%
Operating Margin
-1,241,813.64% -344,986.32% -215,087.18%
EBIT Margin
-1,259,631.82% -363,760.00% -221,141.03%
Profit (Net Income) Margin
-1,170,863.64% -344,489.47% -218,214.10%
Tax Burden Percent
100.17% 100.00% 100.00%
Interest Burden Percent
92.79% 94.70% 98.68%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-351.15% -345.03% -296.16%
ROIC Less NNEP Spread (ROIC-NNEP)
-335.08% -326.32% -281.43%
Return on Net Nonoperating Assets (RNNOA)
296.02% 289.52% 253.40%
Return on Equity (ROE)
-55.13% -55.51% -42.76%
Cash Return on Invested Capital (CROIC)
-331.21% -325.17% -280.49%
Operating Return on Assets (OROA)
-46.51% -47.20% -36.85%
Return on Assets (ROA)
-43.24% -44.70% -36.36%
Return on Common Equity (ROCE)
-55.13% -55.51% -42.76%
Return on Equity Simple (ROE_SIMPLE)
-61.01% -63.89% -51.05%
Net Operating Profit after Tax (NOPAT)
-191 -229 -235
NOPAT Margin
-869,269.55% -241,490.42% -150,561.03%
Net Nonoperating Expense Percent (NNEP)
-16.08% -18.71% -14.73%
Return On Investment Capital (ROIC_SIMPLE)
-45.30% -44.79% -
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
296,386.36% 75,445.26% 50,836.54%
R&D to Revenue
874,086.36% 255,698.95% 164,350.64%
Operating Expenses to Revenue
1,241,913.64% 345,086.32% 215,187.18%
Earnings before Interest and Taxes (EBIT)
-277 -346 -345
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-263 -331 -331
Valuation Ratios
- - -
Price to Book Value (P/BV)
1.06 1.05 1.36
Price to Tangible Book Value (P/TBV)
1.06 1.05 1.36
Price to Revenue (P/Rev)
20,300.07 5,685.98 5,814.63
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.50 1.47 4.29
Enterprise Value to Revenue (EV/Rev)
3,338.75 924.49 2,008.29
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-0.88 -0.89 -0.90
Leverage Ratio
1.28 1.24 1.18
Compound Leverage Factor
1.18 1.18 1.16
Debt to Total Capital
0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
-3.61 -1.91 0.72
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
8.54 12.38 9.84
Quick Ratio
8.23 12.10 9.63
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-180 -216 -222
Operating Cash Flow to CapEx
-28,861.67% -15,681.60% -4,248.10%
Free Cash Flow to Firm to Interest Expense
-996.57 0.00 0.00
Operating Cash Flow to Interest Expense
-1,106.63 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-1,110.46 0.00 0.00
Efficiency Ratios
- - -
Asset Turnover
0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00
Capital & Investment Metrics
- - -
Invested Capital
49 60 73
Invested Capital Turnover
0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-11 -13 -12
Enterprise Value (EV)
73 88 313
Market Capitalization
447 540 907
Book Value per Share
$2.01 $3.04 $4.62
Tangible Book Value per Share
$2.01 $3.04 $4.62
Total Capital
422 512 667
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-373 -452 -594
Capital Expenditures (CapEx)
0.69 1.52 5.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-25 -27 -42
Debt-free Net Working Capital (DFNWC)
268 422 475
Net Working Capital (NWC)
268 422 475
Net Nonoperating Expense (NNE)
66 98 106
Net Nonoperating Obligations (NNO)
-373 -452 -594
Total Depreciation and Amortization (D&A)
14 14 14
Debt-free, Cash-free Net Working Capital to Revenue
-111,877.27% -28,064.21% -27,066.67%
Debt-free Net Working Capital to Revenue
1,217,559.09% 444,248.42% 304,548.72%
Net Working Capital to Revenue
1,217,559.09% 444,248.42% 304,548.72%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($1.32) ($2.09) $0.00
Adjusted Weighted Average Basic Shares Outstanding
194.81M 156.93M 0.00
Adjusted Diluted Earnings per Share
($1.32) ($2.09) $0.00
Adjusted Weighted Average Diluted Shares Outstanding
194.81M 156.93M 0.00
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
217.26M 169.09M 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-180 -220 -235
Normalized NOPAT Margin
-819,260.91% -231,730.95% -150,561.03%
Pre Tax Income Margin
-1,168,850.00% -344,489.47% -218,214.10%
Debt Service Ratios
- - -
EBIT to Interest Expense
-1,531.04 0.00 0.00
NOPAT to Interest Expense
-1,056.57 0.00 0.00
EBIT Less CapEx to Interest Expense
-1,534.88 0.00 0.00
NOPAT Less CapEx to Interest Expense
-1,060.41 0.00 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Allogene Therapeutics

This table displays calculated financial ratios and metrics derived from Allogene Therapeutics' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
0.00% -100.00% -100.00% -26.67% -77.89% 0.00% 0.00% -50.82% -99.87% 0.00%
EBITDA Growth
28.67% -7.35% 14.70% 36.30% 11.85% 19.14% -11.12% -26.66% -1,827.90% -6.57%
EBIT Growth
27.87% -6.43% 14.05% 34.98% 11.12% 18.61% -10.53% -25.19% -6,298.95% -8.34%
NOPAT Growth
28.93% -13.93% 11.31% 29.86% 11.77% 23.63% -5.15% -23.88% -4,053.32% -6.20%
Net Income Growth
30.12% -6.43% 16.25% 34.98% 16.42% 25.09% -5.94% -25.19% -119,436.05% -6.35%
EPS Growth
44.90% 13.51% 35.19% 44.93% 31.94% 36.21% -3.85% -23.21% -7,300.00% -1.75%
Operating Cash Flow Growth
31.67% 20.56% -2.80% 16.12% 13.51% -16.53% -45.44% 2.34% -36.67% 2.50%
Free Cash Flow Firm Growth
32.11% 14.16% -105.77% -50.01% 15.83% 36.46% 60.14% 63.14% -37.57% 29.56%
Invested Capital Growth
-18.13% -24.60% 1.21% -8.55% -18.06% -9.61% -31.64% -37.78% -14.53% -1.93%
Revenue Q/Q Growth
0.00% 0.00% -100.00% -48.84% -4.55% 0.00% -26.67% -68.42% 0.00% 0.00%
EBITDA Q/Q Growth
7.24% -2.94% -10.18% 32.92% -39.59% 18.20% 17.72% 6.18% -28.05% -12.41%
EBIT Q/Q Growth
6.89% -2.18% -9.76% 31.63% -37.39% 17.49% 16.96% 5.58% -25.82% -12.05%
NOPAT Q/Q Growth
15.72% -0.48% -2.77% 18.36% -35.10% 21.78% 18.72% -2.73% -16.94% -7.70%
Net Income Q/Q Growth
9.58% 0.10% -2.09% 25.07% -37.71% 21.39% 20.74% 2.59% -23.43% -11.18%
EPS Q/Q Growth
15.63% 8.57% 7.89% 22.45% -32.43% 31.48% 21.74% 4.17% -24.14% -11.54%
Operating Cash Flow Q/Q Growth
16.81% 30.62% -13.76% -4.08% 3.28% 10.23% 7.18% -7.32% -30.30% -12.05%
Free Cash Flow Firm Q/Q Growth
-3.08% 39.91% -18.45% 7.49% -30.33% -44.04% 13.65% 48.08% 1.60% 9.65%
Invested Capital Q/Q Growth
-18.77% -12.87% 12.85% 2.50% -25.19% 16.97% 1.97% -8.16% -17.48% -11.53%
Profitability Metrics
- - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% -279,295.45% -431,547.62% -295,090.91% -360,759.09% -321,536.67% -108,221.05% 0.00%
Operating Margin
0.00% 0.00% 0.00% -315,927.27% -405,280.95% -286,345.45% -366,090.91% -330,306.67% -101,537.89% 0.00%
EBIT Margin
0.00% 0.00% 0.00% -295,454.55% -448,104.76% -311,327.27% -377,318.18% -333,226.67% -111,450.53% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% -295,454.55% -408,466.67% -283,122.73% -360,145.45% -333,226.67% -108,030.53% 0.00%
Tax Burden Percent
100.74% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
87.66% 90.94% 93.01% 100.00% 91.15% 90.94% 95.45% 100.00% 96.93% 98.81%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% -299.43% -405.33% -401.74% -446.94% -330.29% -139.81% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% -295.89% -400.32% -398.59% -443.30% -325.48% -134.91% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 259.80% 355.17% 347.78% 390.86% 286.13% 121.47% 0.00%
Return on Equity (ROE)
0.00% 0.00% 0.00% -39.62% -50.16% -53.96% -56.08% -44.16% -18.34% 0.00%
Cash Return on Invested Capital (CROIC)
-331.21% -268.86% -295.02% -315.87% -325.17% -271.40% -260.22% -237.12% -280.49% -183.80%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% -38.56% -58.14% -65.77% -64.55% -48.67% -18.57% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% -38.56% -53.00% -59.81% -61.61% -48.67% -18.00% 0.00%
Return on Common Equity (ROCE)
0.00% 0.00% 0.00% -39.62% -50.16% -53.96% -56.08% -44.16% -18.34% 0.00%
Return on Equity Simple (ROE_SIMPLE)
0.00% -61.12% -54.25% -63.35% 0.00% -59.01% -58.59% -60.87% 0.00% -32.12%
Net Operating Profit after Tax (NOPAT)
-42 -50 -50 -49 -60 -44 -56 -69 -68 -58
NOPAT Margin
0.00% 0.00% 0.00% -221,149.09% -283,696.67% -200,441.82% -256,263.64% -231,214.67% -71,076.53% 0.00%
Net Nonoperating Expense Percent (NNEP)
-4.26% -3.54% -3.27% -3.53% -5.01% -3.15% -3.64% -4.81% -4.90% -3.32%
Return On Investment Capital (ROIC_SIMPLE)
-10.03% - - - -11.63% - - - - -
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 78,486.36% 82,019.05% 77,459.09% 84,200.00% 62,946.67% 22,107.37% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 237,540.91% 260,290.48% 208,986.36% 281,990.91% 267,460.00% 79,388.42% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 316,027.27% 405,380.95% 286,445.45% 366,190.91% 330,406.67% 101,495.79% 0.00%
Earnings before Interest and Taxes (EBIT)
-68 -73 -71 -65 -94 -68 -83 -100 -106 -84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-65 -70 -68 -61 -91 -65 -79 -96 -103 -80
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.06 1.26 0.77 1.64 1.05 0.91 1.16 1.21 1.36 2.10
Price to Tangible Book Value (P/TBV)
1.06 1.26 0.77 1.64 1.05 0.91 1.16 1.21 1.36 2.10
Price to Revenue (P/Rev)
20,300.07 13,616.56 6,124.44 8,687.83 5,685.98 3,144.23 4,930.84 5,710.54 5,814.63 20.49
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.50 3.02 0.00 5.80 1.47 0.35 2.49 2.81 4.29 10.18
Enterprise Value to Revenue (EV/Rev)
3,338.75 4,235.52 0.00 4,090.35 924.49 167.67 1,159.01 1,509.45 2,008.29 11.90
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.88 -0.87 -0.88 -0.88 -0.89 -0.87 -0.88 -0.88 -0.90 -0.90
Leverage Ratio
1.28 1.24 1.25 1.27 1.24 1.21 1.21 1.18 1.18 1.15
Compound Leverage Factor
1.12 1.13 1.16 1.27 1.13 1.10 1.15 1.18 1.14 1.14
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-2.35 -1.23 -1.44 0.12 -0.62 -0.01 0.71 0.50 1.68 4.99
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
8.54 9.35 12.25 12.80 12.38 12.58 9.18 8.08 9.84 11.64
Quick Ratio
8.23 8.95 11.92 12.46 12.10 12.37 8.99 7.91 9.63 11.30
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-31 -31 -51 -43 -46 -36 -25 -29 -55 -56
Operating Cash Flow to CapEx
-14,279.38% -10,283.22% 0.00% -698,737.50% -29,672.38% -462,750.00% -21,478.13% -6,438.55% -3,669.98% -21,369.96%
Free Cash Flow to Firm to Interest Expense
0.00 -305.43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 -441.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 -445.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.63
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
49 60 69 61 60 80 68 67 73 89
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.85
Increase / (Decrease) in Invested Capital
-11 -20 0.83 -5.74 -13 -8.52 -32 -41 -12 -1.75
Enterprise Value (EV)
73 182 -48 356 88 28 170 189 313 902
Market Capitalization
447 586 398 756 540 531 725 714 907 1,553
Book Value per Share
$2.01 $2.22 $3.01 $2.73 $3.04 $3.48 $4.27 $4.10 $4.62 $5.15
Tangible Book Value per Share
$2.01 $2.22 $3.01 $2.73 $3.04 $3.48 $4.27 $4.10 $4.62 $5.15
Total Capital
422 464 515 461 512 583 623 592 667 740
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-373 -403 -446 -400 -452 -503 -554 -525 -594 -651
Capital Expenditures (CapEx)
0.26 0.43 0.00 0.01 0.18 0.01 0.29 1.04 1.69 0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-25 -20 -25 -20 -27 -30 -45 -49 -42 -32
Debt-free Net Working Capital (DFNWC)
268 272 420 364 422 436 447 422 475 520
Net Working Capital (NWC)
268 272 420 364 422 436 447 422 475 520
Net Nonoperating Expense (NNE)
18 16 16 16 26 18 23 31 35 25
Net Nonoperating Obligations (NNO)
-373 -403 -446 -400 -452 -503 -554 -525 -594 -651
Total Depreciation and Amortization (D&A)
3.23 3.21 3.64 3.56 3.48 3.57 3.64 3.51 3.07 3.86
Debt-free, Cash-free Net Working Capital to Revenue
-111,877.27% -45,860.47% -38,167.69% -23,436.78% -28,064.21% -17,566.27% -30,327.89% -39,475.20% -27,066.67% -42.27%
Debt-free Net Working Capital to Revenue
1,217,559.09% 632,195.35% 645,875.38% 418,931.03% 444,248.42% 257,880.47% 304,340.14% 337,504.00% 304,548.72% 686.22%
Net Working Capital to Revenue
1,217,559.09% 632,195.35% 645,875.38% 418,931.03% 444,248.42% 257,880.47% 304,340.14% 337,504.00% 304,548.72% 686.22%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.27) ($0.32) ($0.35) ($0.38) ($0.49) ($0.37) ($0.53) ($0.68) ($0.72) ($0.58)
Adjusted Weighted Average Basic Shares Outstanding
194.81M 209.19M 190.03M 169.13M 156.93M 167.65M 146.80M 144.56M 143.15M 143.66M
Adjusted Diluted Earnings per Share
($0.27) ($0.32) ($0.35) ($0.38) ($0.49) ($0.37) ($0.53) ($0.68) ($0.72) ($0.58)
Adjusted Weighted Average Diluted Shares Outstanding
194.81M 209.19M 190.03M 169.13M 156.93M 167.65M 146.80M 144.56M 143.15M 143.66M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
217.26M 209.67M 209.11M 170.85M 169.09M 168.28M 167.63M 145.84M 144.50M 144.21M
Normalized Net Operating Profit after Tax (NOPAT)
-42 -43 -47 -49 -60 -44 -56 -69 -68 -58
Normalized NOPAT Margin
0.00% 0.00% 0.00% -221,149.09% -283,696.67% -200,441.82% -256,263.64% -231,214.67% -71,076.53% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% -295,454.55% -408,466.67% -283,122.73% -360,145.45% -333,226.67% -108,030.53% 0.00%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 -728.98 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 -502.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 -733.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 -506.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Allogene Therapeutics' Financials

When does Allogene Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Allogene Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Allogene Therapeutics' net income changed over the last 2 years?

Allogene Therapeutics' net income appears to be on a downward trend, with a most recent value of -$257.59 million in 2024, falling from -$340.41 million in 2022. The previous period was -$327.27 million in 2023. View Allogene Therapeutics' forecast to see where analysts expect Allogene Therapeutics to go next.

What is Allogene Therapeutics's operating income?
Allogene Therapeutics's total operating income in 2024 was -$273.20 million, based on the following breakdown:
  • Total Gross Profit: $22 thousand
  • Total Operating Expenses: $273.22 million
How has Allogene Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Allogene Therapeutics' total revenue changed from $156 thousand in 2022 to $22 thousand in 2024, a change of -85.9%.

How much debt does Allogene Therapeutics have?

Allogene Therapeutics' total liabilities were at $126.53 million at the end of 2024, a 3.1% decrease from 2023, and a 18.2% decrease since 2022.

How much cash does Allogene Therapeutics have?

In the past 2 years, Allogene Therapeutics' cash and equivalents has ranged from $61.90 million in 2022 to $83.16 million in 2023, and is currently $75.22 million as of their latest financial filing in 2024.

How has Allogene Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Allogene Therapeutics' book value per share changed from 4.62 in 2022 to 2.01 in 2024, a change of -56.5%.



This page (NASDAQ:ALLO) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners